Skip to main content
Erschienen in: Clinical Research in Cardiology 12/2015

01.12.2015 | Original Paper

Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis

verfasst von: Sebastian Ewen, Markus R. Meyer, Bodo Cremers, Ulrich Laufs, Andreas G. Helfer, Dominik Linz, Ingrid Kindermann, Christian Ukena, Michel Burnier, Stefan Wagenpfeil, Hans H. Maurer, Michael Böhm, Felix Mahfoud

Erschienen in: Clinical Research in Cardiology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Renal denervation can reduce blood pressure in patients with uncontrolled hypertension. The adherence to prescribed antihypertensive medication following renal denervation is unknown. This study investigated adherence to prescribed antihypertensive treatment by liquid chromatography–high resolution tandem mass spectrometry in plasma and urine at baseline and 6 months after renal denervation in 100 patients with resistant hypertension, defined as baseline office systolic blood pressure ≥140 mmHg despite treatment with ≥3 antihypertensive agents. At baseline, complete adherence to all prescribed antihypertensive agents was observed in 52 patients, 46 patients were partially adherent, and two patients were completely non-adherent. Baseline office blood pressure was 167/88 ± 19/16 mmHg with a corresponding 24-h blood pressure of 154/86 ± 15/13 mmHg. Renal denervation significantly reduced office and ambulatory blood pressure at 6-month follow-up by 15/5 mmHg (p < 0.001/p < 0.001) and 8/4 mmHg (p < 0.001/p = 0.001), respectively. Mean adherence to prescribed treatment was significantly reduced from 85.0 % at baseline to 80.7 %, 6 months after renal denervation (p = 0.005). The blood pressure decrease was not explained by improvements in adherence following the procedure. Patients not responding to treatment significantly reduced their drug intake following the procedure. Adherence was highest for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta blockers (>90 %) and lowest for vasodilators (21 %). In conclusion, renal denervation can reduce office and ambulatory blood pressure in patients with resistant hypertension despite a significant reduction in adherence to antihypertensive treatment after 6 months.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219. doi:10.1093/eurheartj/eht151 CrossRefPubMed Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219. doi:10.​1093/​eurheartj/​eht151 CrossRefPubMed
5.
Zurück zum Zitat Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S (2013) Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 166(2):306–314.e7. doi:10.1016/j.ahj.2013.04.016 CrossRefPubMed Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S (2013) Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 166(2):306–314.e7. doi:10.​1016/​j.​ahj.​2013.​04.​016 CrossRefPubMed
7.
Zurück zum Zitat Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA (2012) Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126(25):2976–2982. doi:10.1161/CIRCULATIONAHA.112.130880 CrossRefPubMed Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA (2012) Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126(25):2976–2982. doi:10.​1161/​CIRCULATIONAHA.​112.​130880 CrossRefPubMed
9.
Zurück zum Zitat Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V (2013) Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 34(28):2132–2140. doi:10.1093/eurheartj/eht197 PubMedCentralCrossRefPubMed Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V (2013) Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 34(28):2132–2140. doi:10.​1093/​eurheartj/​eht197 PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Azizi M, Sapoval M, Gosse P et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385(9981):1957–1965. doi:10.1016/S0140-6736(14)61942-5 CrossRefPubMed Azizi M, Sapoval M, Gosse P et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385(9981):1957–1965. doi:10.​1016/​S0140-6736(14)61942-5 CrossRefPubMed
12.
Zurück zum Zitat Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383(9917):622–629. doi:10.1016/s0140-6736(13)62192-3 CrossRefPubMed Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383(9917):622–629. doi:10.​1016/​s0140-6736(13)62192-3 CrossRefPubMed
16.
Zurück zum Zitat Waeber B, Feihl F (2013) Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy. EuroIntervention 9(Suppl R):R29–R34. doi:10.4244/eijv9sra6 CrossRefPubMed Waeber B, Feihl F (2013) Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy. EuroIntervention 9(Suppl R):R29–R34. doi:10.​4244/​eijv9sra6 CrossRefPubMed
18.
Zurück zum Zitat Ewen S, Baumgarten T, Rettig-Ewen V, Mahfoud F, Griese-Mammen N, Schulz M, Böhm M, Laufs U (2015) Analyses of drugs stored at home by elderly patients with chronic heart failure. Clin Res Cardiol 104(4):320–327. doi:10.1007/s00392-014-0783-2 CrossRefPubMed Ewen S, Baumgarten T, Rettig-Ewen V, Mahfoud F, Griese-Mammen N, Schulz M, Böhm M, Laufs U (2015) Analyses of drugs stored at home by elderly patients with chronic heart failure. Clin Res Cardiol 104(4):320–327. doi:10.​1007/​s00392-014-0783-2 CrossRefPubMed
20.
Zurück zum Zitat Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, Schmieder RE (2014) What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention 9(9):1027–1035. doi:10.4244/EIJV9I9A175 PubMed Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, Schmieder RE (2014) What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention 9(9):1027–1035. doi:10.​4244/​EIJV9I9A175 PubMed
21.
Zurück zum Zitat Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. Anal Bioanal Chem 400(1):79–88. doi:10.1007/s00216-010-4398-9 CrossRefPubMed Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. Anal Bioanal Chem 400(1):79–88. doi:10.​1007/​s00216-010-4398-9 CrossRefPubMed
22.
Zurück zum Zitat Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J, Meyer MR, Maurer HH (2015) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC–HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. Drug Test Anal 7(5):368–375. doi:10.1002/dta.1682 CrossRefPubMed Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J, Meyer MR, Maurer HH (2015) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC–HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. Drug Test Anal 7(5):368–375. doi:10.​1002/​dta.​1682 CrossRefPubMed
23.
26.
Zurück zum Zitat Rosa J, Widimsky P, Tousek P et al (2015) Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension 65(2):407–413. doi:10.1161/hypertensionaha.114.04019 CrossRefPubMed Rosa J, Widimsky P, Tousek P et al (2015) Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension 65(2):407–413. doi:10.​1161/​hypertensionaha.​114.​04019 CrossRefPubMed
29.
Zurück zum Zitat Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR (2001) Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19(2):335–341CrossRefPubMed Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR (2001) Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19(2):335–341CrossRefPubMed
Metadaten
Titel
Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis
verfasst von
Sebastian Ewen
Markus R. Meyer
Bodo Cremers
Ulrich Laufs
Andreas G. Helfer
Dominik Linz
Ingrid Kindermann
Christian Ukena
Michel Burnier
Stefan Wagenpfeil
Hans H. Maurer
Michael Böhm
Felix Mahfoud
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 12/2015
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-015-0905-5

Weitere Artikel der Ausgabe 12/2015

Clinical Research in Cardiology 12/2015 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.